Biogen Inc. (NASDAQ:BIIB) is the Best Biotech Stock.
On April 20, 2026, Reuters reported that Biogen Inc. (NASDAQ:BIIB) had agreed to pay up to $850 million for the exclusive Greater China rights to felzartamab. It is an experimental immune therapy developed by Chinese biotech TJ Biopharma, bringing the drug’s global commercial coverage to a close.
TJ Biopharma will receive $100 million up front. It will also add up to $750 million in milestone payments and further royalties on Greater China sales. Biogen Inc. (NASDAQ:BIIB) shares rose 1.3% in premarket trading.
Felzartamab is currently in the last stage trials for IgA nephropathy and primary membranous nephropathy. These are two kidney diseases that can lead to organ failure. China’s health regulator is separately assessing the drug for multiple myeloma.
Biogen Inc. (NASDAQ:BIIB) obtained felzartamab as part of its $1.8 billion takeover of Human Immunology Biosciences in 2024. In April 2025, the two companies launched the partnership in China. If authorities approve the medicine, Biogen Inc. (NASDAQ:BIIB) plans to oversee regional manufacture and commercialization. TJ Biopharma continues to produce it at its Hangzhou facility for myeloma.
Biogen Inc. (NASDAQ:BIIB) is a biopharmaceutical firm that works on identifying, making, and providing drugs for neurological and neurodegenerative diseases.
While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
